Esperion Therapeutics (ESPR) Cash from Operations Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Cash from Operations Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.46% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 425.00% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -22.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.51% |
| Dec 31, 2025 | 229.44% |
| Sep 30, 2025 | 87.87% |
| Jun 30, 2025 | -336.11% |
| Mar 31, 2025 | -142.04% |
| Dec 31, 2024 | 5.68% |
| Sep 30, 2024 | -82.79% |
| Jun 30, 2024 | 70.89% |
| Mar 31, 2024 | 199.03% |
| Dec 31, 2023 | 12.75% |
| Sep 30, 2023 | 54.88% |
| Jun 30, 2023 | 51.02% |
| Mar 31, 2023 | -39.41% |
| Dec 31, 2022 | 26.40% |
| Sep 30, 2022 | 38.07% |
| Jun 30, 2022 | -5.57% |
| Mar 31, 2022 | 56.22% |
| Dec 31, 2021 | 15.82% |
| Sep 30, 2021 | 20.19% |
| Jun 30, 2021 | -134.34% |